Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research Prescription for Better Access

In this episode, we explore the 340B Drug Pricing Program, an essential yet complex component of the American drug supply landscape that aims to enable healthcare entities to offer more affordable medication to underserved populations. We interview Antonio Ciaccia, a drug pricing and 340B expert who provides an in-depth look at how the program works, its financial incentives, and how stakeholders have exploited this well-intentioned program, all to the detriment of patients.


Antonio Ciaccia, President, 3 Axis Advisors and CEO, 46brooklyn Research, an Ohio non-profit Corporation
46brooklyn
Ohio Pharmacist Association
3 Axis Advisors
Medicaid
340B Program
340B Litigation
340 Eligibility, HRSA
Covered Entities
Medicaid Drug Rebate Program
Obamacare

Indian Health Service
"Money from Sick People," Report from 46Brooklyn

Medicare
Pharmacy Benefit Managers (PBMs)

Jamie Robinson, Health Economist

Medical terminology referenced in this episode:


Novolog

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.